Clinical trials
Hepatocellular Carcinoma clinical trials
Below are recruiting hepatocellular carcinoma clinical trials, each written for real people, not researchers. We’re tracking 589 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05096715RecruitingPhase 1
Testing atezolizumab plus bevacizumab with SBRT for advanced liver cancer
This Phase 1 trial tests how well a combination treatment works for liver cancer that cannot be removed with surgery or other local treatments. It combines two immune/targeted medicines with a focused type of radiation (SBRT) to control the tumors.
Boston, MassachusettsAges 18 years+ - NCT04224636RecruitingPhase 2
Atezolizumab and bevacizumab with optional repeat chemo liver procedure
This Phase 2 trial tests whether starting with atezolizumab plus bevacizumab, then using an on-demand TACE (a targeted liver artery chemo treatment) can control hepatocellular carcinoma (liver cancer). It also compares this approach to giving both medicines together with an initial TACE right away, aiming to improve tumor control and outcomes.
BonnAges 18 years+ - NCT06172205RecruitingPhase 3
Two ways to give chemo plus immunotherapy for advanced liver cancer
This study tests whether a combination of chemotherapy (FOLFOX) plus two immunotherapy drugs (Camrelizumab and Apatinib) works better when given directly into the liver artery (HAIC) versus through a vein. It's for people with advanced liver cancer who haven't had other treatments yet.
Guangzhou, GuangdongAges 18–75 - NCT06060769Recruiting
MRI risk assessment for liver cancer in chronic liver disease
This study uses special MRI scans to better predict liver cancer risk in people with chronic liver disease. It may help doctors identify high-risk patients earlier and improve monitoring.
Zhuhai, GuangdongAges 18 years+ - NCT07018947RecruitingPhase 2
Atezolizumab and bevacizumab before and after surgery for liver cancer
This trial tests whether adding two drugs (atezolizumab and bevacizumab) before and after surgery can lower the chance of liver cancer coming back in people with high-risk HCC. You must be eligible for surgical removal of your tumor.
Badalona, BarcelonaAges 18 years+ - NCT06930573RecruitingPhase 4
AK112 for high-risk liver cancer after surgery
This study tests a new drug called AK112 (a combination antibody targeting two proteins that help tumors grow) after surgery for liver cancer that has a high chance of returning. The goal is to see if it can prevent the cancer from coming back.
Zhengzhou, HenanAges 18–75 - NCT07273708Recruiting
Immune cell study in liver cancer patients on immunotherapy
This study looks at how your immune cells respond to two specific immunotherapy-based treatments for advanced liver cancer. Researchers want to understand why some patients respond well and others do not, which could help improve future care.
Pavia, LombardyAges 18–90 - NCT07272200Recruiting
Genes and alcohol in liver cancer: a study
This study looks at how your genes and alcohol use together affect the risk of liver cancer. It may help find ways to prevent cancer in people with fatty liver disease or moderate alcohol intake.
Milan, MilanoAges 45–75 - NCT07242417RecruitingEarly Phase 1
TC-G203 for adults with GPC3-positive advanced solid tumors
This trial tests an experimental cell therapy (TC-G203) for people with advanced solid tumors that have a specific protein called GPC3. It aims to see if this treatment is safe and effective for those who haven't responded to standard treatments.
Beijing, Beijing MunicipalityAges 18–75 - NCT07249112Recruiting
Genomic study of metabolic fatty liver disease
This study aims to understand the genetic factors behind metabolic fatty liver disease (MASLD) by comparing patients with advanced liver scarring or liver cancer to healthy blood donors. It may help doctors better predict and treat the disease in the future.
Milan, MilanoAges 18–90 - NCT06909708Recruiting
Comparing two liver cancer treatments for unresectable tumors
This trial compares two treatments for liver cancer that cannot be removed by surgery: SIRT (a type of internal radiation) and cTACE (a type of targeted chemo). It aims to see which is more effective for patients with limited tumor spread and good liver function.
Nanjing, JiangsuAges 18 years+ - NCT05985798RecruitingPhase 3
Immunotherapy plus TACE vs. Targeted Therapy plus TACE for Advanced Liver Cancer
This trial is testing a combination of two immunotherapy drugs (sintilimab and bevacizumab) plus a procedure called TACE (chemoembolization) against a targeted therapy pill (lenvatinib) plus TACE for people with advanced liver cancer. The goal is to see which approach works better to shrink tumors and improve outcomes.
Guangzhou, GuangdongAges 18 years+ - NCT05967143Recruiting
Registry study for first-time SIR-Spheres in liver tumors
This is an observational (real-world) study that follows people with certain unresectable liver tumors who are getting SIR-Spheres for the first time. It helps doctors understand how this treatment is used in routine care and what outcomes patients experience.
Clichy, CedexAges 18 years+ - NCT07099274RecruitingPhase 2
Combination treatment for advanced liver cancer
This trial tests a combination of two immunotherapy drugs, TACE (a procedure to block blood flow to tumors), and lenvatinib (a targeted therapy) for people with liver cancer that has not responded to initial treatment. It aims to see if this combination can help shrink tumors or slow cancer growth.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT06360042RecruitingPhase 2
Immunotherapy plus anti-angiogenic drugs for advanced liver cancer
This trial is testing a combination of immunotherapy (anti-PD-1/PD-L1) and drugs that block blood vessel growth (anti-angiogenic agents) as a first treatment for people with advanced liver cancer that cannot be removed by surgery. The goal is to see if this combination can shrink tumors or slow their growth.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07475026RecruitingPhase 3
Combination therapy before surgery for high-risk liver cancer
This trial tests whether a combination of two drugs (tislelizumab and lenvatinib) given before surgery can lower the risk of liver cancer coming back in people with early-stage but high-risk disease.
TianjinAges 18–75 - NCT07381634RecruitingPhase 2
Testing ondansetron to reduce immunotherapy side effects in liver cancer
This study tests whether adding ondansetron (a common anti-nausea drug) can reduce side effects from immunotherapy in people with liver cancer. If you are starting a specific combination treatment for liver cancer, you may be eligible.
Wenzhou, ZhejiangAges 18–80 - NCT07059494RecruitingPhase 4
Combination therapy for liver cancer before transplant
This trial tests a combination of two drugs (atezolizumab and bevacizumab) plus a targeted radiation treatment (Y-90 radioembolization) for people with liver cancer who are waiting for a liver transplant. The goal is to see if this treatment can help control the cancer and improve transplant outcomes.
New York, New YorkAges 18 years+ - NCT07521852RecruitingPhase 2
New drug combination with immunotherapy for liver cancer
This trial tests a new drug called CVM-1118 combined with an immunotherapy drug (sintilimab) and a procedure called TACE (a catheter-based treatment that delivers medicine directly to tumors) in people with hepatocellular carcinoma (liver cancer) that cannot be cured by surgery. The goal is to see if this combination is effective and safe.
Fuzhou, FujianAges 18 years+ - NCT03198546RecruitingPhase 1
CAR T therapy for advanced liver cancer with GPC3
This Phase 1 study tests a personalized immune-cell treatment (CAR T cells) for advanced liver cancer that has the GPC3 protein. It aims to see whether these engineered cells can find and kill cancer cells safely and help shrink the cancer.
Guangzhou, GuangdongAges 18–75 - NCT03259867RecruitingPhase 2
TACE plus immune therapy for liver or stomach cancer
This trial tests a combination treatment using a targeted liver procedure plus an immune “checkpoint” medicine to slow cancer growth. It may help people with advanced liver cancer (HCC) or metastatic stomach cancer when standard treatments have not worked.
Orange, CaliforniaAges 18–80 - NCT03539822RecruitingPhase 1/Phase 2
Cabozantinib and immunotherapy for advanced stomach or bowel cancers
This early-phase study tests a combination of anti-cancer pills and immune-based treatment for people with advanced stomach, esophagus, colorectal, or liver cancer. It aims to shrink tumors and see how safe the treatment is, including whether biopsy testing can help guide future care.
Westwood, KansasAges 18 years+ - NCT03612726Recruiting
Study for people with unresectable liver cancer
This trial looks at overall survival (how long people live) in real-world patients with unresectable liver cancer. It may help researchers understand outcomes outside of tightly controlled studies.
BeijingAges 18 years+ - NCT03686709Recruiting
Extra scan and blood testing with Y90 radioembolization
This study looks at how well Y90 “radioembolization” treatment delivers radiation and how much radiation reaches your body. If you can safely get extra PET/CT scans and blood tests around your treatment, you may be invited to participate.
Knoxville, TennesseeAges 18 years+
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for hepatocellular carcinoma?
- Yes. Clin2 currently lists 589 recruiting hepatocellular carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a hepatocellular carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a hepatocellular carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.